• Shenzhen Hepalink Pharmaceutical Group will hold an extraordinary general meeting in Shenzhen on Sept. 22, 2026.
• Shareholders will vote on raising the internal-funds cap for wealth management product purchases to RMB 3.5 billion from RMB 2.5 billion.
• A separate vote will cover a revised 2026 credit-line and bank-guarantee framework, keeping total credit lines at RMB 18.54 billion.
• The proposal also cuts the total guarantee limit to RMB 7.5 billion from RMB 10.09 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12308752), on August 31, 2026, and is solely responsible for the information contained therein.